Launched its second biosimilar product ‘Rituximab under the brand name ‘MABALL’. This enabled the company to join select biotech companies with the capability to develop, manufacture and commercialize complex monoclonal antibodies (MAB’s).
Launched its first biosimilar product ‘Darbepoetin alfa’ under the brand name ‘Derise’
Set up one of India’s largest finished dosage manufacturing facility, Jadcherla, Andhra Pradesh.
Hetero forays into biosimilar business, established its biologics unit at Jadcherla, India.
Asia’s largest manufacturing SEZ complex for APIs was established at Vishakhapatnam, India.
Hetero’s finished dosage manufacturing plant based at Hyderabad, India received approval from US FDA.
Hetero was recognized as one of the Indian companies in the world to produce the life-saving drug ‘Oseltamivir’ for Bird Flu and Swine flu.
Hetero received the first US FDA approval for API manufacturing facility, Hyderabad, India.
Hetero begins formulations in its first finished dosage manufacturing facility in Hyderabad.
Hetero became one of the first Indian companies to offer affordable anti-retroviral APIs to the world for the treatment for HIV/AIDS. Its pioneering efforts made the company as the world leader in production of anti-retroviral drugs, both in APIs and finished dosages.
Honoured with the National Award for ‘Best efforts in Research and Development’
Established its state-of-the-art R&D centre - Hetero Research Foundation at Hyderabad, India. This facility earned Hetero the distinction of being the first company in India to develop generic processes for more than 20 APIs in a span of 3 years.
Production commences at Hetero’s first API manufacturing facility, Hyderabad, India.
Established Hetero Group